Critical Comparison: AtriCure (NASDAQ:ATRC) versus Meihua International Medical Technologies (NASDAQ:MHUA) – Defense World
Posted by admin on Jul 11th, 2022
AtriCure (NASDAQ:ATRC – Get Rating) and Meihua International Medical Technologies (NASDAQ:MHUA – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Analyst Ratings
This is a breakdown of current recommendations and price targets for AtriCure and Meihua International Medical Technologies, as reported by MarketBeat.
AtriCure presently has a consensus target price of $83.20, indicating a potential upside of 90.04%. Given AtriCure’s higher possible upside, analysts clearly believe AtriCure is more favorable than Meihua International Medical Technologies.
Earnings & Valuation
This table compares AtriCure and Meihua International Medical Technologies’ gross revenue, earnings per share and valuation.
AtriCure has higher revenue and earnings than Meihua International Medical Technologies.
Insider and Institutional Ownership
95.4% of AtriCure shares are held by institutional investors. 2.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares AtriCure and Meihua International Medical Technologies’ net margins, return on equity and return on assets.
Summary
AtriCure beats Meihua International Medical Technologies on 6 of the 8 factors compared between the two stocks.
About AtriCure (Get Rating)
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
About Meihua International Medical Technologies (Get Rating)
Meihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles. It also distributes disposable medical devices sourced from other manufacturers to customers in China. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.
Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.
Bausch + Lomb (NYSE:BLCO) and STAAR Surgical (NASDAQ:STAA) Financial Review